Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Weger, W; Kränke, B; Gerger, A; Salmhofer, W; Aberer, E.
Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
J Am Acad Dermatol. 2008; 59(2 Suppl 1):S4-S6
Doi: 10.1016/j.jaad.2007.06.040
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Kränke Birger
- Weger Wolfgang
- Co-authors Med Uni Graz
- Aberer Elisabeth
- Gerger Armin
- Salmhofer Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Capecitabine, an oral fluoropyrimidine and 5-fluorouracil (FU) prodrug recently approved for the treatment of metastatic colon and breast cancer, is currently under investigation in patients with gastric cancer. It has the advantage of oral administration, and good tolerability with its activity being comparable with intravenous 5-FU. Lupus erythematosus and lupuslike drug eruptions have been observed after 5-FU treatment, but so far no cases of subacute cutaneous lupus erythematosus have been described in patients treated either with capecitabine or 5-FU. We report a patient who developed subacute cutaneous lupus erythematosus after administration of 5-FU and capecitabine.
- Find related publications in this database (using NLM MeSH Indexing)
- Acute Disease -
- Administration, Oral -
- Aged -
- Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects
- Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives
- Fatal Outcome -
- Female -
- Fluorouracil - administration & dosage Fluorouracil - adverse effects Fluorouracil - analogs & derivatives
- Humans -
- Lupus Erythematosus, Cutaneous - chemically induced Lupus Erythematosus, Cutaneous - drug therapy
- Severity of Illness Index -
- Steroids - therapeutic use
- Stomach Neoplasms - drug therapy